Subjective cognitive decline (SCD) is regarded as the first clinical manifestation in the
Alzheimer's disease (AD) continuum. Investigating populations with SCD is important for …

Background Serum glial fibrillary acidic protein (GFAP) and neurofilament light (NfL) are
putative non-amyloid blood-based biomarkers indicative of ongoing inflammatory and …

Large phenotypically diverse research cohorts with both amyloid and tau PET have only
recently come into existence. Our objective was to determine relationships between the …

Objective To determine the nature and extent of minor neuropsychological deficits in
patients with subjective cognitive decline (SCD) and their association with CSF biomarkers …

Alzheimer's disease (AD) pathology begins decades before the onset of clinical symptoms. It
is recognized as a clinicobiological entity, being detectable in vivo independently of the …

Background and Objectives Previous research has shown that elevated blood C-reactive
protein (CRP) is associated with increased Alzheimer disease (AD) risk only in APOE ε4 …

Introduction Despite advances in imaging retinal amyloidosis, a quantitative and
topographical investigation of retinal amyloid beta burden in patients with cognitive decline …

Plasma biomarkers are promising prognostic tools in individuals with subjective cognitive
decline (SCD). We aimed to investigate the relationships of baseline plasma amyloid beta …

Abstract Purpose In vivo Alzheimer's disease (AD) biomarkers for tau pathology are
cerebrospinal fluid (CSF) phosphorylated tau (p-tau) and [18 F] flortaucipir positron emission …

Purpose In order to achieve comparability of image quality, harmonisation of PET system
performance is imperative. In this study, prototype harmonisation criteria for PET brain …